Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist

Brain Research Bulletin
Lee A DawsonPing Li


Although recent data has shown that 5-HT(6) receptor antagonists' can enhance basal cholinergic and glutamatergic neurotransmission in the cortex and hippocampus, the distribution of this receptor within terminal regions of the dopaminergic system suggests a possible role for this receptor in the modulation of dopamine (DA). Therefore, the role of the 5-HT(6) receptor was examined in the rat striatum in the presence and absence of the DA transport inhibitor/releaser, amphetamine. Amphetamine (0.3mg/kg s.c.) induced a selective increase in extracellular DA reaching a maximum of 311.3+/-73.5% of preinjection levels. Administration of SB-271046 (1 and 10mg/kg s.c.) followed by amphetamine produced an augmentation of amphetamine-induced changes in both DA and 5-hydroxytryptamine (5-HT), reaching maximum levels of 510.1+/-110.5% and 271+/-93.4% of preinjection values, respectively. Similarly, local infusion of amphetamine (100 nM) resulted in an increase in striatal DA levels reaching a maximum of 365.7+/-73.3% of preinfusion values. However, combination treatment with SB-271046 (1mg/kg s.c.) and amphetamine produced no augmentation of amphetamine-induced increases in extracellular levels of DA or in any other neurotransmitter measu...Continue Reading


Feb 24, 2007·Progress in Neurobiology·Christian P MüllerMaria A De Souza Silva
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Apr 29, 2014·Behavioural Brain Research·Christian P Müller, Judith R Homberg
Jan 29, 2011·Pharmacological Reports : PR·Katarzyna FijałMałgorzata Filip
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cindy K J LiebenRudy Schreiber
Oct 23, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M Garcia-AllozaM J Ramírez


Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·L K HeislerL H Tecott
Jan 12, 1999·British Journal of Pharmacology·A BoursonA J Sleight
Feb 3, 1999·Annals of the New York Academy of Sciences·M YoshiokaK Mori
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Aug 6, 2000·British Journal of Pharmacology·Carol RoutledgeD N Middlemiss
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee A DawsonP Li
Feb 19, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Grégory PorrasUmberto Spampinato

Related Concepts

Serotonin 6 receptor
Dialysis Solutions
Biochemical Pathway
Cortex Bone Disorders
Adrenal Cortex Diseases
Prefrontal Cortex

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.